Drugs; foods containing vaccines or vaccine material included within term; misbranded if not conspicuously labeled
Summary
HB316 would amend Alabama’s food and drug laws to treat any food containing a vaccine or vaccine material as a “drug” for purposes of the state’s adulterated and misbranded drug provisions. The bill adds a new statutory definition of “vaccine or vaccine material” as a substance intended for use in humans to stimulate antibodies and immunity, prepared from a disease-causing agent or a synthetic substitute, and approved or authorized by the U.S. Food and Drug Administration. It also makes a food containing vaccine material subject to labeling requirements and misbranding rules under the chapter.
Under the bill, a food product containing vaccine material would be misbranded unless its package, label, or brand bears the words “Contains Vaccine or Vaccine Material” in a font of uniform size and prominence and states that the article of food is classified as a drug under the chapter. The bill also makes technical and stylistic updates to existing code language, including modernizing references such as “man” to “humans.” The effective date would be October 1, 2025.
Impact
HB316 would expand the scope of Alabama Code Sections 20-1-20 and 20-1-25 by adding foods containing vaccine or vaccine material to the statutory definition of “drug” and by creating a specific labeling requirement for those products. This would subject such foods to the state’s drug misbranding framework and give the Department of Agriculture and Industries additional regulatory authority over labeling and enforcement for affected products. The bill primarily affects manufacturers, distributors, and retailers of food products that contain vaccine material, as well as state regulators responsible for food and drug compliance.
Sentiment
The bill appears to have been introduced and referred to the House Health Committee without recorded floor votes or committee transcript discussion in the provided materials, so there is no documented formal debate or vote history to gauge broad legislative sentiment. Based on the bill’s sponsorship and caption, the measure is framed as a consumer-labeling and regulatory clarification bill rather than a major policy overhaul. The available record suggests it was still pending committee action at the time of the snapshot.
Contention
The central point of contention is the bill’s treatment of foods containing vaccine material as drugs, which could raise questions about regulatory scope, product classification, and labeling burdens for affected businesses. Supporters would likely view the measure as a transparency and public-notice requirement, while opponents could argue that it creates an unusual or overly broad category of regulated products and may be difficult to apply in practice. Because no committee transcript or vote record is provided, no specific legislator or stakeholder positions are documented in the available materials.